Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Ionizing Radiation | Research

Bcl-2-associated transcription factor 1 Ser290 phosphorylation mediates DNA damage response and regulates radiosensitivity in gastric cancer

Authors: Jia Liu, Jingyi Li, Zhao Sun, Yangmiao Duan, Fengqin Wang, Guangwei Wei, Jing-Hua Yang

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

DNA damage response plays critical roles in tumor pathogenesis and radiotherapy resistance. Protein phosphorylation is a critical mechanism in regulation of DNA damage response; however, the key mediators for radiosensitivity in gastric cancer still needs further exploration.

Methods

A quick label-free phosphoproteomics using high-resolution mass spectrometry and an open search approach was applied to paired tumor and adjacent tissues from five patients with gastric cancer. The dysregulated phosphoproteins were identified and their associated-pathways analyzed using Gene Set Enrichment Analysis (GSEA). The mostly regulated phosphoproteins and their potential functions were validated by the specific antibodies against the phosphorylation sites. Specific protein phosphorylation was further analyzed by functional and clinical approaches.

Results

832 gastric cancer-associated unique phosphorylated sites were identified, among which 25 were up- and 52 down-regulated. Markedly, the dysregulated phosphoproteins were primarily enriched in DNA-damage-response-associated pathways. Particularly, the phosphorylation of Bcl-2-associated transcription factor 1 (BCLAF1) at Ser290 was significantly upregulated in tumor. The upregulation of BCLAF1 Ser290 phosphorylation (pBCLAF1 (Ser290)) in tumor was confirmed by tissue microarray studies and further indicated in association with poor prognosis of gastric cancer patients. Eliminating the phosphorylation of BCLAF1 at Ser290 suppressed gastric cancer (GC) cell proliferation. Upregulation of pBCLAF1 (Ser290) was found in association with irradiation-induced γ-H2AX expression in the nucleus, leading to an increased DNA damage repair response, and a marked inhibition of irradiation-induced cancer cell apoptosis.

Conclusions

The phosphorylation of BCLAF1 at Ser290 is involved in the regulation of DNA damage response, indicating an important target for the resistance of radiotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Busuttil RA, George J, House CM, Lade S, Mitchell C, Di Costanzo NS, et al. SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. Gastric Cancer. 2020;24(3):589–601.CrossRef Busuttil RA, George J, House CM, Lade S, Mitchell C, Di Costanzo NS, et al. SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. Gastric Cancer. 2020;24(3):589–601.CrossRef
2.
go back to reference Hu K, Wang S, Wang Z, Li L, Huang Z, Yu W, et al. Clinicopathological risk factors for gastric cancer: a retrospective cohort study in China. BMJ Open. 2019;9(9):e030639.CrossRef Hu K, Wang S, Wang Z, Li L, Huang Z, Yu W, et al. Clinicopathological risk factors for gastric cancer: a retrospective cohort study in China. BMJ Open. 2019;9(9):e030639.CrossRef
3.
go back to reference Min BH, Kim KM, Park CK, Lee JH, Rhee PL, Rhee JC, et al. Outcomes of endoscopic submucosal dissection for differentiated-type early gastric cancer with histological heterogeneity. Gastric Cancer. 2015;18(3):618–26.CrossRef Min BH, Kim KM, Park CK, Lee JH, Rhee PL, Rhee JC, et al. Outcomes of endoscopic submucosal dissection for differentiated-type early gastric cancer with histological heterogeneity. Gastric Cancer. 2015;18(3):618–26.CrossRef
4.
go back to reference Lee J, Chung SJ, Choi JM, Han YM, Kim JS. Clinicopathologic characteristics and long-term outcome of gastric cancer patients with family history: seven-year follow-up study for korean health check-up subjects. Gastroenterol Res Pract. 2020;2020:4028136.PubMedPubMedCentral Lee J, Chung SJ, Choi JM, Han YM, Kim JS. Clinicopathologic characteristics and long-term outcome of gastric cancer patients with family history: seven-year follow-up study for korean health check-up subjects. Gastroenterol Res Pract. 2020;2020:4028136.PubMedPubMedCentral
5.
go back to reference Qiao YQ, Zheng L, Jia B, Wang WH, Zheng XH, Fan LL, et al. Risk factors for surgical-site infections after radical gastrectomy for gastric cancer: a study in China. Chin Med J (Engl). 2020;133(13):1540–5.CrossRef Qiao YQ, Zheng L, Jia B, Wang WH, Zheng XH, Fan LL, et al. Risk factors for surgical-site infections after radical gastrectomy for gastric cancer: a study in China. Chin Med J (Engl). 2020;133(13):1540–5.CrossRef
6.
go back to reference Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2013;18(9):1013–21.CrossRef Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2013;18(9):1013–21.CrossRef
7.
go back to reference Sawyer TK, Shakespeare WC, Wang Y, Sundaramoorthi R, Huang WS, Metcalf CA 3rd, et al. Protein phosphorylation and signal transduction modulation: chemistry perspectives for small-molecule drug discovery. Med Chem. 2005;1(3):293–319.CrossRef Sawyer TK, Shakespeare WC, Wang Y, Sundaramoorthi R, Huang WS, Metcalf CA 3rd, et al. Protein phosphorylation and signal transduction modulation: chemistry perspectives for small-molecule drug discovery. Med Chem. 2005;1(3):293–319.CrossRef
8.
go back to reference Medvedev AE, Piao W, Shoenfelt J, Rhee SH, Chen H, Basu S, et al. Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance. J Biol Chem. 2007;282(22):16042–53.CrossRef Medvedev AE, Piao W, Shoenfelt J, Rhee SH, Chen H, Basu S, et al. Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance. J Biol Chem. 2007;282(22):16042–53.CrossRef
9.
go back to reference Proud CG. Phosphorylation and Signal Transduction Pathways in Translational Control. Cold Spring Harb Perspect Biol. 2019;11:7.CrossRef Proud CG. Phosphorylation and Signal Transduction Pathways in Translational Control. Cold Spring Harb Perspect Biol. 2019;11:7.CrossRef
10.
go back to reference Kuznetsova KG, Solovyeva EM, Kuzikov AV, Gorshkov MV, Moshkovskii SA. Modification of cysteine residues for mass spectrometry-based proteomic analysis: facts and artifacts. Biomed Khim. 2020;66(1):18–29.CrossRef Kuznetsova KG, Solovyeva EM, Kuzikov AV, Gorshkov MV, Moshkovskii SA. Modification of cysteine residues for mass spectrometry-based proteomic analysis: facts and artifacts. Biomed Khim. 2020;66(1):18–29.CrossRef
11.
go back to reference Lao YW, Gungormusler-Yilmaz M, Shuvo S, Verbeke T, Spicer V, Krokhin OV. Chromatographic behavior of peptides containing oxidized methionine residues in proteomic LC-MS experiments: Complex tale of a simple modification. J Proteomics. 2015;125:131–9.CrossRef Lao YW, Gungormusler-Yilmaz M, Shuvo S, Verbeke T, Spicer V, Krokhin OV. Chromatographic behavior of peptides containing oxidized methionine residues in proteomic LC-MS experiments: Complex tale of a simple modification. J Proteomics. 2015;125:131–9.CrossRef
12.
go back to reference Chouchani ET, James AM, Fearnley IM, Lilley KS, Murphy MP. Proteomic approaches to the characterization of protein thiol modification. Curr Opin Chem Biol. 2011;15(1):120–8.CrossRef Chouchani ET, James AM, Fearnley IM, Lilley KS, Murphy MP. Proteomic approaches to the characterization of protein thiol modification. Curr Opin Chem Biol. 2011;15(1):120–8.CrossRef
13.
go back to reference Yan GR, Ding W, Xu SH, Xu Z, Xiao CL, Yin XF, et al. Characterization of phosphoproteins in gastric cancer secretome. OMICS. 2011;15(1–2):83–90.CrossRef Yan GR, Ding W, Xu SH, Xu Z, Xiao CL, Yin XF, et al. Characterization of phosphoproteins in gastric cancer secretome. OMICS. 2011;15(1–2):83–90.CrossRef
14.
go back to reference Mou SJ, Yang PF, Liu YP, Xu N, Jiang WW, Yue WJ. BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma. Life Sci. 2020;242:117177.CrossRef Mou SJ, Yang PF, Liu YP, Xu N, Jiang WW, Yue WJ. BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma. Life Sci. 2020;242:117177.CrossRef
15.
go back to reference Wen Y, Zhou X, Lu M, He M, Tian Y, Liu L, et al. Bclaf1 promotes angiogenesis by regulating HIF-1alpha transcription in hepatocellular carcinoma. Oncogene. 2019;38(11):1845–59.CrossRef Wen Y, Zhou X, Lu M, He M, Tian Y, Liu L, et al. Bclaf1 promotes angiogenesis by regulating HIF-1alpha transcription in hepatocellular carcinoma. Oncogene. 2019;38(11):1845–59.CrossRef
16.
go back to reference Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q, et al. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun. 2014;5:4581.CrossRef Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q, et al. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun. 2014;5:4581.CrossRef
17.
go back to reference Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, et al. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016;7(8):e2342.CrossRef Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, et al. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016;7(8):e2342.CrossRef
18.
19.
go back to reference Shao AW, Sun H, Geng Y, Peng Q, Wang P, Chen J, et al. Bclaf1 is an important NF-kappaB signaling transducer and C/EBPbeta regulator in DNA damage-induced senescence. Cell Death Differ. 2016;23(5):865–75.CrossRef Shao AW, Sun H, Geng Y, Peng Q, Wang P, Chen J, et al. Bclaf1 is an important NF-kappaB signaling transducer and C/EBPbeta regulator in DNA damage-induced senescence. Cell Death Differ. 2016;23(5):865–75.CrossRef
20.
go back to reference Li X, He Z, Cheng B, Fang Q, Ma D, Lu T, et al. Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism. Cancer Biol Ther. 2018;19(9):825–34.CrossRef Li X, He Z, Cheng B, Fang Q, Ma D, Lu T, et al. Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism. Cancer Biol Ther. 2018;19(9):825–34.CrossRef
21.
go back to reference Vohhodina J, Barros EM, Savage AL, Liberante FG, Manti L, Bankhead P, et al. The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export. Nucleic Acids Res. 2017;45(22):12816–33.CrossRef Vohhodina J, Barros EM, Savage AL, Liberante FG, Manti L, Bankhead P, et al. The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export. Nucleic Acids Res. 2017;45(22):12816–33.CrossRef
22.
go back to reference Soodgupta D, White LS, Yang W, Johnston R, Andrews JM, Kohyama M, et al. RAG-Mediated DNA Breaks Attenuate PU.1 Activity in Early B Cells through Activation of a SPIC-BCLAF1 Complex. Cell Rep. 2019;29(4):829–43.CrossRef Soodgupta D, White LS, Yang W, Johnston R, Andrews JM, Kohyama M, et al. RAG-Mediated DNA Breaks Attenuate PU.1 Activity in Early B Cells through Activation of a SPIC-BCLAF1 Complex. Cell Rep. 2019;29(4):829–43.CrossRef
23.
go back to reference Lee YY, Yu YB, Gunawardena HP, Xie L, Chen X. BCLAF1 is a radiation-induced H2AX-interacting partner involved in gammaH2AX-mediated regulation of apoptosis and DNA repair. Cell Death Dis. 2012;3:e359.CrossRef Lee YY, Yu YB, Gunawardena HP, Xie L, Chen X. BCLAF1 is a radiation-induced H2AX-interacting partner involved in gammaH2AX-mediated regulation of apoptosis and DNA repair. Cell Death Dis. 2012;3:e359.CrossRef
24.
go back to reference Liu H, Lu ZG, Miki Y, Yoshida K. Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol. 2007;27(24):8480–91.CrossRef Liu H, Lu ZG, Miki Y, Yoshida K. Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol. 2007;27(24):8480–91.CrossRef
25.
go back to reference Na S, Bandeira N, Paek E. Fast multi-blind modification search through tandem mass spectrometry. Mol Cell Proteomics. 2012;11:M111.010199.CrossRef Na S, Bandeira N, Paek E. Fast multi-blind modification search through tandem mass spectrometry. Mol Cell Proteomics. 2012;11:M111.010199.CrossRef
26.
go back to reference Na S, Kim J, Paek E. MODplus: robust and unrestrictive identification of post-translational modifications using mass spectrometry. Anal Chem. 2019;91:11324–33.CrossRef Na S, Kim J, Paek E. MODplus: robust and unrestrictive identification of post-translational modifications using mass spectrometry. Anal Chem. 2019;91:11324–33.CrossRef
27.
go back to reference Bern M, Kil Y J and Becker C. Byonic: advanced peptide and protein identification software. Curr Protoc Bioinform. 2012;Chapter 13, Unit13 20. Bern M, Kil Y J and Becker C. Byonic: advanced peptide and protein identification software. Curr Protoc Bioinform. 2012;Chapter 13, Unit13 20.
28.
go back to reference Tong M, Yu CY, Shi JW, Huang WW, Qin J. Phosphoproteomics enables molecular subtyping and nomination of kinase candidates for individual patients of diffuse-type gastric cancer. Science. 2019;22:44–57. Tong M, Yu CY, Shi JW, Huang WW, Qin J. Phosphoproteomics enables molecular subtyping and nomination of kinase candidates for individual patients of diffuse-type gastric cancer. Science. 2019;22:44–57.
29.
go back to reference Kasof GM, Goyal L, White E. Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol. 1999;19(6):4390–404.CrossRef Kasof GM, Goyal L, White E. Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol. 1999;19(6):4390–404.CrossRef
30.
go back to reference Heroes E, Van der Hoeven G, Choy MS, Garcia JDP, Ferreira M, Nys M, et al. Structure-guided exploration of SDS22 interactions with protein phosphatase PP1 and the splicing factor BCLAF1. Structure. 2019;27(3):507–18.CrossRef Heroes E, Van der Hoeven G, Choy MS, Garcia JDP, Ferreira M, Nys M, et al. Structure-guided exploration of SDS22 interactions with protein phosphatase PP1 and the splicing factor BCLAF1. Structure. 2019;27(3):507–18.CrossRef
31.
go back to reference Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–8.CrossRef Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–8.CrossRef
32.
go back to reference Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.CrossRef Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.CrossRef
33.
go back to reference Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.CrossRef Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.CrossRef
34.
go back to reference Zhao H, Huang X, Halicka HD, Darzynkiewicz Z. Detection of Histone H2AX Phosphorylation on Ser-139 as an Indicator of DNA Damage. Curr Protoc Cytom. 2019;89(1):e55.PubMed Zhao H, Huang X, Halicka HD, Darzynkiewicz Z. Detection of Histone H2AX Phosphorylation on Ser-139 as an Indicator of DNA Damage. Curr Protoc Cytom. 2019;89(1):e55.PubMed
35.
go back to reference Djuzenova CS, Elsner I, Katzer A, Worschech E, Distel LV, Flentje M, et al. Radiosensitivity in breast cancer assessed by the histone gamma-H2AX and 53BP1 foci. Radiat Oncol. 2013;8:98.CrossRef Djuzenova CS, Elsner I, Katzer A, Worschech E, Distel LV, Flentje M, et al. Radiosensitivity in breast cancer assessed by the histone gamma-H2AX and 53BP1 foci. Radiat Oncol. 2013;8:98.CrossRef
36.
go back to reference Liu J, Jiang G, Mao P, Zhang J, Zhang L, Liu L, et al. Down-regulation of GADD45A enhances chemosensitivity in melanoma. Sci Rep. 2018;8(1):4111.CrossRef Liu J, Jiang G, Mao P, Zhang J, Zhang L, Liu L, et al. Down-regulation of GADD45A enhances chemosensitivity in melanoma. Sci Rep. 2018;8(1):4111.CrossRef
37.
go back to reference Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, et al. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7(4):663–71.CrossRef Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, et al. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7(4):663–71.CrossRef
Metadata
Title
Bcl-2-associated transcription factor 1 Ser290 phosphorylation mediates DNA damage response and regulates radiosensitivity in gastric cancer
Authors
Jia Liu
Jingyi Li
Zhao Sun
Yangmiao Duan
Fengqin Wang
Guangwei Wei
Jing-Hua Yang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-03004-z

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.